ONEOK (OKE) Q3 2026 Earnings Call Transcript

ONEOK reported third-quarter adjusted EBITDA of $2.24 billion, up 6% year over year, and raised its 2026 adjusted EBITDA guidance midpoint by $200 million to approximately $8.55 billion, citing stronger base businesses and the Brazos acquisition. The company completed a $9 billion minority equity investment and extinguished nearly $5.5 billion of debt; S&P and Fitch upgraded its ratings to BBB+, and management lowered its leverage target to approximately 3.25x or below. NGL raw feed throughput rose 6% to nearly 1.7 million barrels per day, while management cited stored NGL inventory as a near-term timing headwind ahead of Medford Phase 1, expected to support earnings from early 2027.

Analysis

The key quality-of-earnings distinction is that the outlook combines durable throughput growth with timing and transaction effects: the near-term uplift from processing stored NGLs is deferred fee income, not a new run-rate, while part of the guidance increase is transaction-related. Medford therefore creates a visible Q1 2027 bridge, but investors should separate that catch-up from recurring growth when assessing the multiple. Narrowing Waha differentials removes a source of volatile optimization revenue; that is a near-term headwind but also reduces reliance on basin congestion and makes contracted gathering, processing and takeaway growth more important.

The balance-sheet reset lowers financing risk, but it was enabled by minority equity capital as well as debt retirement—not solely internally generated deleveraging. Verify the investment’s ongoing economic claims and ownership impact before treating the improved credit profile as unambiguously accretive to per-share value. A lower leverage ceiling is positive only if it constrains acquisition appetite as well as supports organic investment and distributions.

Over 1–3 months, watch Medford commissioning, inventory drawdown and February 2027 guidance; over 6–18 months, the test is whether new processing and takeaway capacity fills on schedule without another material step-up in capital intensity. The contrarian risk is that the market capitalizes a temporary inventory release and producer activity as structural growth before contracted volumes convert to cash flow.

Key Decisions for Investors

• Construct a modest long OKE in tranches on post-call weakness rather than chasing the guidance raise. The near-term catalyst is Medford’s expected Q1 2027 earnings conversion and February guidance; keep sizing modest until the company quantifies the inventory benefit and demonstrates recurring growth.
• Do not underwrite the stored-NGL release as a recurring EBITDA step-up. Track commissioning, actual inventory reduction and fractionation utilization; a delayed start or a materially smaller-than-expected drawdown would weaken the near-term thesis.
• Monitor debt-to-EBITDA, capital spending and shareholder returns together. Reassess if leverage trends toward the 3.5x ceiling, or if spending rises without contracted utilization and cash-flow conversion; also verify the minority investor’s economic rights before judging per-share accretion.
• Treat further Waha-to-Katy spread compression as a watch item, not a standalone short: management says the next-quarter decline is reflected in guidance, but sustained optimization weakness alongside slowing fee-based volumes would falsify the diversified-growth case.